Evaluation of the safety of 1% voriconazole ear drops for the treatment of tympanic membrane perforation-associated suppurative otomycosis.

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Mao Jin, Yuan Zhao, Zhanwei Dong, Yuejiao Zhang, Lei Zhang, Xinxin Yang, Rui Du, Shoude Zhang
{"title":"Evaluation of the safety of 1% voriconazole ear drops for the treatment of tympanic membrane perforation-associated suppurative otomycosis.","authors":"Mao Jin, Yuan Zhao, Zhanwei Dong, Yuejiao Zhang, Lei Zhang, Xinxin Yang, Rui Du, Shoude Zhang","doi":"10.36721/PJPS.2025.38.5.REG.14677.1","DOIUrl":null,"url":null,"abstract":"<p><p>Otomycosis is a common otolaryngologic condition commonly complicated by tympanic membrane perforation (TMP). Although topical voriconazole has been found effective in TMP-free otomycosis, data on its safety in TMP-associated otomycosis are limited. This study was conducted to determine the safety profile of 1% ear drops of voriconazole in a rabbit model of TMP-associated suppurative otomycosis due to a clinical isolate of Aspergillus terreus. The local preparation was applied three times daily for seven consecutive days. Therapeutic efficacy was assessed by otoendoscopy, while safety was established by brainstem auditory evoked potential (BAEP) assessment and scanning electron microscopy (SEM) of cochlear hair cells. Serum levels of voriconazole were also quantified to assess systemic absorption. No difference was noted in pre- and post-treatment auditory thresholds (27 ± 6.75 dB vs. 27 ± 4.83 dB, P > 0.99). SEM examination demonstrated no damage to cochlear hair cells, and serum voriconazole concentrations remained undetectable after application. The results conclude that 1% voriconazole ear drops are safe for the treatment of TMP-associated suppurative otomycosis in this animal model. Limitations are that only one species of fungi and a preparation made at home were utilized, and further studies with other pathogens and commercial preparations are needed.</p>","PeriodicalId":19971,"journal":{"name":"Pakistan journal of pharmaceutical sciences","volume":"38 5","pages":"1775-1783"},"PeriodicalIF":0.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pakistan journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36721/PJPS.2025.38.5.REG.14677.1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Otomycosis is a common otolaryngologic condition commonly complicated by tympanic membrane perforation (TMP). Although topical voriconazole has been found effective in TMP-free otomycosis, data on its safety in TMP-associated otomycosis are limited. This study was conducted to determine the safety profile of 1% ear drops of voriconazole in a rabbit model of TMP-associated suppurative otomycosis due to a clinical isolate of Aspergillus terreus. The local preparation was applied three times daily for seven consecutive days. Therapeutic efficacy was assessed by otoendoscopy, while safety was established by brainstem auditory evoked potential (BAEP) assessment and scanning electron microscopy (SEM) of cochlear hair cells. Serum levels of voriconazole were also quantified to assess systemic absorption. No difference was noted in pre- and post-treatment auditory thresholds (27 ± 6.75 dB vs. 27 ± 4.83 dB, P > 0.99). SEM examination demonstrated no damage to cochlear hair cells, and serum voriconazole concentrations remained undetectable after application. The results conclude that 1% voriconazole ear drops are safe for the treatment of TMP-associated suppurative otomycosis in this animal model. Limitations are that only one species of fungi and a preparation made at home were utilized, and further studies with other pathogens and commercial preparations are needed.

1%伏立康唑滴耳液治疗鼓膜穿孔相关性化脓性耳真菌病的安全性评价。
耳真菌病是一种常见的耳鼻喉疾病,通常并发鼓膜穿孔(TMP)。虽然局部伏立康唑已被发现对无tmp耳真菌病有效,但其在tmp相关耳真菌病中的安全性数据有限。本研究旨在确定1%伏立康唑滴耳液在由土曲霉临床分离株引起的tmp相关化脓性耳真菌病兔模型中的安全性。局部制剂每日应用3次,连续7天。采用耳内窥镜评估治疗效果,脑干听觉诱发电位(BAEP)评估和耳蜗毛细胞扫描电镜(SEM)检查确定治疗安全性。同时定量测定伏立康唑的血清水平以评估全身吸收。治疗前后的听觉阈值差异无统计学意义(27±6.75 dB vs. 27±4.83 dB, P < 0.99)。扫描电镜检查显示耳蜗毛细胞无损伤,使用后血清伏立康唑浓度仍未检测到。结果表明,1%伏立康唑滴耳液治疗该动物模型中与tmp相关的化脓性耳真菌病是安全的。限制是只利用了一种真菌和一种自制的制剂,需要对其他病原体和商业制剂进行进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
211
审稿时长
4.5 months
期刊介绍: Pakistan Journal of Pharmaceutical Sciences (PJPS) is a peer reviewed multi-disciplinary pharmaceutical sciences journal. The PJPS had its origin in 1988 from the Faculty of Pharmacy, University of Karachi as a biannual journal, frequency converted as quarterly in 2005, and now PJPS is being published as bi-monthly from January 2013. PJPS covers Biological, Pharmaceutical and Medicinal Research (Drug Delivery, Pharmacy Management, Molecular Biology, Biochemical, Pharmacology, Pharmacokinetics, Phytochemical, Bio-analytical, Therapeutics, Biotechnology and research on nano particles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信